868755-79-7 Usage
General Description
2-[4-(2-FURYL)PHENYL]-4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLANE, also known as Hel-444, is a boron-containing compound used in organic synthesis. It is a white crystalline powder with a molecular formula of C18H23BO2 and a molecular weight of 284.18 g/mol. 2-[4-(2-FURYL)PHENYL]-4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLANE is commonly used as a reagent in organic chemistry reactions, particularly in the formation of carbon-carbon bonds and as a boron source in various reactions. It is also used in the synthesis of various pharmaceuticals, agrochemicals, and materials. It is important to handle this compound with caution, as it can be harmful if ingested or inhaled and may cause irritation to the skin and eyes.
Check Digit Verification of cas no
The CAS Registry Mumber 868755-79-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,8,7,5 and 5 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 868755-79:
(8*8)+(7*6)+(6*8)+(5*7)+(4*5)+(3*5)+(2*7)+(1*9)=247
247 % 10 = 7
So 868755-79-7 is a valid CAS Registry Number.
InChI:InChI=1/C16H19BO3/c1-15(2)16(3,4)20-17(19-15)13-9-7-12(8-10-13)14-6-5-11-18-14/h5-11H,1-4H3
868755-79-7Relevant articles and documents
Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)
Lagu, Bharat,Kluge, Arthur F.,Tozzo, Effie,Fredenburg, Ross,Bell, Eric L.,Goddeeris, Matthew M.,Dwyer, Peter,Basinski, Andrew,Senaiar, Ramesh S.,Jaleel, Mahaboobi,Tiwari, Nirbhay Kumar,Panigrahi, Sunil K.,Krishnamurthy, Narasimha Rao,Takahashi, Taisuke,Patane, Michael A.
supporting information, p. 935 - 940 (2018/09/06)
The X-ray structure of the previously reported PPARδ modulator 1 bound to the ligand binding domain (LBD) revealed that the amide moiety in 1 exists in the thermodynamically disfavored cis-amide orientation. Isosteric replacement of the cis-amide with five-membered heterocycles led to the identification of imidazole 17 (MA-0204), a potent, selective PPARδ modulator with good pharmacokinetic properties. MA-0204 was tested in vivo in mice and in vitro in patient-derived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); 17 altered the expression of PPARδ target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.
